2026-03211Notice

FDA Hands Fast-Pass Voucher to Rare Disease Kid Drug Maker

Published Date: 2/18/2026

Notice

Summary

The FDA just gave a special priority review voucher to Abeona Therapeutics for their rare pediatric disease treatment, ZEVASKYN, approved in April 2025. This voucher speeds up future drug reviews, helping get important medicines to patients faster. It’s a big win for kids with rare diseases and could save time and money in bringing new treatments to market.

No Economic Impacts Identified for this Document

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
2/18/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register